Sign in

U.S. Uterine Fibroid Market Growth Factors, Development and Forecast to 2023

Rohit Kamble
U.S. Uterine Fibroid Market Growth Factors, Development and Forecast to 2023

U.S. Uterine Fibroid Market Scenario

Uterine fibroids can be referred to as the abnormal growth which generally develops inside or on the wall of the uterus of a woman. Also termed as myomas or leiomyoma, uterine fibroids are non-cancerous growth which causes symptoms like pain in the pelvis and lower back, heavy bleeding during or between the menstrual cycle, and increased menstrual cramps along with the enlargement of the abdomen.

Market Research Future (MRFR) speculates that the “U.S. Uterine Fibroid Market Is Likely To Garner USD 39,993.2 Million, Grabbing a CAGR Of 3.24% During The Forecast Period (2016-2022)”. The surging prevalence of uterine fibroid in the African-American race is considered a propelling factor to the growth of the market.

Avail Free Sample@ https://www.marketresearchfuture.com/sample_request/2394

U.S. Uterine Fibroid Market: Segmental Analysis

The U.S. uterine fibroid market has been segmented on the basis of type, diagnosis, and treatment.

By mode of type, the U.S. uterine fibroid market has been segmented into intramural fibroids, subserosal fibroids, submucosal fibroids, and others.

By mode of diagnosis, the U.S. uterine fibroid market has been segmented into computed tomography (CT), medical resonance imaging (MRI) scanners, ultrasounds, and others.

By mode of treatment, the U.S. uterine fibroid market has been segmented into magnetic resonance-guided focused ultrasound, uterine fibroid embolization, endometrial ablation, myolysis, hysterectomy, and myomectomy. Among these, hysterectomy and myomectomy are minimally invasive surgeries which are likely to gain prominence in the long run. These surgeries being minimally invasive, reduces the chances of infection after surgery, shorter hospital stays, and minimal recovery time. These advantages of hysterectomy and myomectomy are likely to contribute to the segment’s growth.

Market Potential and Pitfalls

Uterine fibroids are spreading over the entire U.S. at a rapid pace mainly due to the increased prevalence of uterine fibroids in the African-American race. The high blood pressure, the heredity of uterine fibroids, and low levels of vitamin D are considered some of the top factors causing uterine fibroids. Several treatment options available such as pharmacotherapy, self-help techniques, invasive surgical procedures, and uterine artery embolization are propelling the market growth in the U.S.

The introduction of minimally invasive surgeries such as myomectomy and hysterectomy for treating the excruciating pain of uterine fibroids is expected to encourage the market growth. Such surgeries have reduced the chances of infection, reduced the hospital stay, and, lowered the recovery time, thereby contributing to the growth.

On the contrary, it has also been observed that the procedures such as myomectomy and hysterectomy are covering the uterine Fibroid treatment despite the side effects associated with it. Moreover, the high cost-containment measures undertaken by governments along with the ongoing healthcare reforms are restricting the market growth in the U.S.

Competitive Dashboard

The prominent players operating the U.S. uterine fibroids market comprises,

Cook Medical Inc. (US)

AstraZeneca (England)

GE Healthcare (U.K.)

Boston Scientific Corporation (US)

Hologic (U.S.)

AbbVie Inc. (U.S.)

and others.

Browse the Full Research Report@  https://www.marketresearchfuture.com/reports/uterine-fibroid-market-2394

Regional Insights

The U.S. uterine fibroid market is expanding at a steady pace with a CAGR of 3.24% by the end of 2022. Economies like Texas, California, New York, and Florida are estimated to witness the highest prevalence of uterine fibroids. North America has been recorded to witness the largest market share due to the increased awareness among the population of the region, easy accessibility to advanced technologies, and an established healthcare sector. The presence of a high number of clinics and ambulatory surgical centers and hospitals in this region has further contributed to the market’s growth. A huge number of people are undergoing hormonal disorders which are further encouraging the market growth. Moreover, the increased incidences of uterine cancer is another propelling factor.


Table 1 U.S. Uterine Fibroid Market, By Type, 2013-2022 (USD Million)

Table 2 U.S. Uterine Fibroid Market, By Diagnosis, 2013-2022 (USD Million)

Table 3 U.S. Uterine Fibroid Market, By Treatment, 2013-2022 (USD Million)

Table 4 U.S. Uterine Fibroid Market, By Treatment Type, 2013-2022 (USD Million)

Table 5 Pipeline Products For Uterine Fibroids

Table 6 Astrazeneca: Key Development

Table 7 Boston Scientific Corporation: Key Development

…To be continues

Rohit Kamble
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more